Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer
This study is investigating if a medicine called dutasteride can help prevent low-grade, non-muscle-invasive bladder cancer (NMIBC) from returning. This type of bladder cancer often comes back after treatment, which can lead to more operations and affect a person's quality of life. Currently, there isn't a routine preventative treatment for this type of cancer that is both effective and easy to use. Dutasteride is a tablet taken by mouth that is generally well-tolerated. The study hopes to find out if this medicine can offer a simple way to reduce the chance of the cancer coming back, as well as checking its safety in women. We continually want to find effective options that improve outcomes for patients.
במבט חטוף
על מה המחקר הזה?
This study is focused on a common type of bladder cancer called low-grade, non-muscle-invasive bladder cancer. While treatments for this condition are available, the cancer often tends to come back. When it recurs, it means more hospital visits and procedures for patients, which can be disruptive and stressful. Finding a way to prevent these recurrences could significantly improve the lives of many people.
Currently, there isn't a widely used and well-tolerated preventive medicine for this specific type of bladder cancer. This research aims to see if an existing medicine called dutasteride could fill this gap. Dutasteride works by blocking certain hormones in the body. It's already known to be generally well-tolerated and is taken as a simple tablet.
The main goal of this research is to discover if dutasteride can effectively reduce the risk of this bladder cancer returning. The study will also carefully check for any side effects and see how safe it is for both men and women to take. Ultimately, the hope is to find a straightforward and effective way to help patients avoid repeated cancer recurrences.
נקודות עיקריות
- This study explores a new way to prevent bladder cancer from returning.
- It tests an existing medicine called dutasteride for low-grade bladder cancer.
- Participation involves taking a daily tablet and regular check-ups for up to two years.
- The study aims to improve quality of life by reducing cancer recurrences.
- It includes both men and women to understand safety and effectiveness broadly.
מי עשוי להיות זכאי?
To join this study, you need to be aged 18 or older and have a confirmed diagnosis of low-grade, non-muscle-invasive bladder cancer. This means your cancer hasn't grown into the bladder muscle and is considered a less aggressive type. You also should not have been recommended for certain other bladder cancer treatments, like BCG or powerful chemotherapy injections into the bladder, as your main treatment recently.
There are also some reasons why you might not be able to join. For example, if you've recently had or are scheduled for BCG treatment or powerful bladder chemotherapy. Also, if you have certain other medical conditions like severe liver problems, unstable heart conditions, or other cancers treated with hormone therapy, you might not be suitable. Women who are pregnant or planning to become pregnant, or men planning to father children, would have specific discussions with the study team about contraception due to the medication.
If you've previously had a severe allergic reaction to dutasteride or a similar drug called finasteride, you wouldn't be able to participate. The study team will review all your medical information carefully to make sure it's safe for you to take part.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- האם אתה בן 18 או יותר?
- Have you been diagnosed with low-grade, non-muscle-invasive bladder cancer?
- Have you NOT been recently recommended for BCG or certain strong bladder chemotherapy?
- Are you able to take a daily tablet and attend regular appointments?
- Do you have a severe allergy to dutasteride or finasteride?
מה כרוך בהשתתפות?
If you decide to join this study and are found to be suitable, you will take a medicine called dutasteride, a 0.5 mg tablet, once every day. You'll continue taking this medicine until your bladder cancer recurs or for a maximum of two years, whichever comes first. If your cancer does come back within this period, you might still be able to continue the dutasteride treatment for up to the full two years, with the decision made in discussion with your doctor.
During the study, you will have regular check-ups to monitor your health, how you are responding to the treatment, and to check for any side effects. This will involve appointments at the clinic and potentially some tests. The study team will carefully explain the schedule of these appointments and what each one involves. The full duration of your participation could be up to two years, depending on your individual response.
סיכונים ותועלות פוטנציאליים
מיקומים (1)
- CHU de Québec - Université Lavalמיקוד מאומתקוויבק, קנדה· גיוס
שאלות נפוצות
What kind of bladder cancer is this study for?
This study is for people with low-grade, non-muscle-invasive bladder cancer, which means the cancer hasn't spread into the bladder muscle.
What is dutasteride, and how do I take it?
Dutasteride is a tablet that you would take once a day by mouth. It aims to block certain hormones in the body.
כמה זמן אהיה במחקר?
You could be in the study for up to two years, or until your cancer returns, whichever happens first.
Is this medicine new?
Dutasteride is an existing medicine, but its use for preventing bladder cancer recurrence in this specific way is being studied.
What if the cancer comes back while I'm on the study?
If your cancer returns, you might be offered the option to continue taking dutasteride for up to two years, depending on discussions with your doctor.
כיצד לגלות עוד
Paul Toren Principal Investigator, MD
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.